EN DE
Watch Egetis Therapeutics AB (publ) for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Egetis Therapeutics AB (publ) (EGTX) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Egetis Therapeutics AB (publ) stock SEK 6.25, price SEK 11.10, that is 43.7% below the price, quality 38 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0003815604

ET Egetis Therapeutics AB (publ) logo Thin data Nov 11, 2026

Egetis Therapeutics AB (publ)

EGTX · ST
Very expensive, weak quality

Our calculation puts a fair price 44% below what the stock costs today.

Low debt
Revenue last quarter +23% vs. a year ago.
Mixed Growth (revenue 5y +8.9 %/yr in SEK)
Fair value kr 6.25 · Strongly overvalued
Quality 38/100
Negative free cash flow
Trails peers (1/7)
Narrow moat 13/100 · thin data
Thin data
Estimate
Watch Egetis Therapeutics AB (publ) for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 11.12 kr 3.01 Fair Value kr 6.25 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range kr 3.01 – kr 11.12 · fair‑value band kr 4.69 – kr 7.81 · the kr 11.10 price screens above the kr 6.25 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Egetis Therapeutics AB (publ) in your weekly email

Every Wednesday you see whether Egetis Therapeutics AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally.

Show moreShow less

It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency.

The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.

Stock analysis

Egetis Therapeutics AB (publ) (EGTX) currently trades at kr 11.10, while our estimate is kr 6.25, 44% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 4.69 (bear) to kr 7.81 (bull), the price of kr 11.10 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Egetis Therapeutics AB (publ) reported revenue of 62.4M SEK in FY2025 versus 38.2M SEK in FY2021, a compound +13.0%/yr. Reported net income was −343M SEK in FY2025.

Key figures

Market cap 5.0B SEK (≈ $505M) Small · P/S ratio 73.7 · EPS (TTM) kr −1.10 · Return on equity −152% · Return on assets (EBIT) −38.5% (5-year average) · Operating margin −631% · Revenue (TTM) 70.0M SEK · Revenue growth (YoY) +23.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 157% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −44%, EGTX screens richer than that median.

Fair Value

Bear kr 4.69 Fair Value kr 6.25 Bull kr 7.81
Price kr 11.10 · Downside -43.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 54
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 92
Debt, balance sheet and risk of trouble
Investment 92
Does it invest with discipline instead of growing at any price?
Low Volatility 41
How calm the share price moves, does not count
Price momentum 100
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 100
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 24/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+35.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.9%
Start year 2020 (pandemic)
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+95.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−438.7% (2020) → −555.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

EGTX screens overvalued: fair value 44% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Egetis Therapeutics AB (publ) with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Below median
Fair Value upside −43.7% · Bottom 25%
Profitability
Return on assets −53.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 23.0% · Above median
Balance sheet
Debt / equity 0.13× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 14.71× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 71.18× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)93 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs EGTX
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs EGTX
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs EGTX
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs EGTX
argenx SE ARGX $971.55 $908.40 −7% vs EGTX
CSL Limited CSL A$201.68 A$181.40 −10% vs EGTX
Moderna, Inc MRNA $250.83 $158.70 −37% vs EGTX
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs EGTX
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs EGTX
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs EGTX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Egetis Therapeutics AB (publ): fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Egetis Therapeutics AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/EGTX

Frequently asked questions

Is Egetis Therapeutics AB (publ) (EGTX) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is kr 6.25 versus a price of kr 11.10, about 44% lower (overvalued).
What is the fair value of EGTX?
Our estimate for Egetis Therapeutics AB (publ) is kr 6.25 (as of Nov 11, 2026), built from audited fundamentals. The current price: kr 11.10.
What is the quality score of EGTX?
Egetis Therapeutics AB (publ) has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Egetis Therapeutics AB (publ) (EGTX)?
Our calculated price target is the estimate of kr 6.25 (as of Nov 11, 2026). Cautious scenario kr 4.69, optimistic scenario kr 7.81. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Egetis Therapeutics AB (publ) stock forecast for 2026?
Our estimate puts fair value at kr 6.25, about 44% lower versus a price of kr 11.10 (overvalued). Cautious scenario kr 4.69, optimistic scenario kr 7.81. The calculation is refreshed regularly with new filings.
What is the revenue of Egetis Therapeutics AB (publ) (EGTX)?
Egetis Therapeutics AB (publ) reported trailing-twelve-month revenue of about 70.0M SEK (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of Egetis Therapeutics AB (publ) (EGTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Egetis Therapeutics AB (publ) it is kr 6.25 per share (as of Nov 11, 2026), against a price of kr 11.10.
Is Egetis Therapeutics AB (publ) stock overvalued or undervalued in 2026?
As of Nov 11, 2026, EGTX trades above its calculated fair value: price kr 11.10, fair value kr 6.25, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EGTX?
No. The price is what the market pays today (kr 11.10); the fair value is what the company's own numbers justify (kr 6.25). For Egetis Therapeutics AB (publ) the two are kr 4.85 per share apart. That gap is exactly why we show both numbers side by side.
How much is Egetis Therapeutics AB (publ) worth?
The market values Egetis Therapeutics AB (publ) at about 5.0B SEK (market capitalisation, as of Nov 11, 2026). Per share that is kr 11.10; our models calculate a fair value of kr 6.25 per share.
What do the bullish and bearish scenarios say about EGTX?
Our models span a range for Egetis Therapeutics AB (publ): cautious scenario kr 4.69, base kr 6.25, optimistic kr 7.81 per share (as of Nov 11, 2026, price kr 11.10). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Egetis Therapeutics AB (publ) (EGTX)?
Balance-sheet figures for Egetis Therapeutics AB (publ) (as of Nov 11, 2026): return on equity −152.2%, debt of 0.13 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is EGTX from its 52-week high?
Egetis Therapeutics AB (publ) trades at kr 11.10, at its 52-week high of kr 11.12 and 157% above the low of kr 4.32 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 6.25 is for.
Which stocks are comparable to Egetis Therapeutics AB (publ)?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Egetis Therapeutics AB (publ) stock attractive at the current price?
The data as of Nov 11, 2026: price kr 11.10, calculated fair value kr 6.25 (−44%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Egetis Therapeutics AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Egetis Therapeutics AB (publ) (EGTX)?
The closing price on Nov 10, 2026 was kr 11.10. Our estimate is kr 6.25, about 44% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Egetis Therapeutics AB (publ) right now?
The price sits above even our optimistic bull case (kr 7.81). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Egetis Therapeutics AB (publ)

How large is the market capitalisation of Egetis Therapeutics AB (publ) (EGTX)?
The market capitalisation of Egetis Therapeutics AB (publ) is 5.0B SEK (≈ $505M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Egetis Therapeutics AB (publ) (EGTX)?
The price-to-sales ratio of Egetis Therapeutics AB (publ) is 73.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Egetis Therapeutics AB (publ) (EGTX)?
Earnings per share at Egetis Therapeutics AB (publ) are kr −1.10. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Egetis Therapeutics AB (publ) (EGTX)?
The return on equity (ROE) of Egetis Therapeutics AB (publ) is −152% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Egetis Therapeutics AB (publ) (EGTX)?
On an EBIT basis the return on assets of Egetis Therapeutics AB (publ) is −38.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Egetis Therapeutics AB (publ) (EGTX)?
The operating margin of Egetis Therapeutics AB (publ) is −631% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Egetis Therapeutics AB (publ) (EGTX)?
Revenue at Egetis Therapeutics AB (publ) is growing +23.0% versus a year earlier (3y avg +40.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Egetis Therapeutics AB (publ) (EGTX) generate?
The free cash flow of Egetis Therapeutics AB (publ) is −269M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Egetis Therapeutics AB (publ) (EGTX) hold?
Egetis Therapeutics AB (publ) holds more cash than debt, 139M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Egetis Therapeutics AB (publ) in the live analysis

One click puts Egetis Therapeutics AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.